Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$1.4 million.

  • ImmunityBio's Change in Account Payables rose 8439.81% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year decrease of 5487.63%. This contributed to the annual value of -$3.2 million for FY2024, which is 5109.64% up from last year.
  • Latest data reveals that ImmunityBio reported Change in Account Payables of -$1.4 million as of Q3 2025, which was up 8439.81% from -$6.2 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Change in Account Payables registered a high of $6.5 million during Q1 2021, and its lowest value of -$8.9 million during Q3 2024.
  • Over the past 5 years, ImmunityBio's median Change in Account Payables value was -$1.4 million (recorded in 2025), while the average stood at -$343631.6.
  • As far as peak fluctuations go, ImmunityBio's Change in Account Payables crashed by 75835.24% in 2023, and later surged by 54580.84% in 2024.
  • ImmunityBio's Change in Account Payables (Quarter) stood at -$3.5 million in 2021, then surged by 112.32% to $437000.0 in 2022, then tumbled by 758.35% to -$2.9 million in 2023, then dropped by 11.71% to -$3.2 million in 2024, then surged by 56.69% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, -$6.2 million for Q2 2025, and $6.4 million during Q1 2025.